Opinion|Videos|February 6, 2025
Obe-Cel and MRD Outcomes: Insights and Comparisons
Panelists discuss how real-world outcomes data from the CIBMTR registry on brexucabtagene autoleucel (brexu-cel) presented at the American Society of Hematology Annual Meeting and Exposition (ASH 2024) align with clinical practice, as well as the key findings from the FELIX trial, including minimal residual disease (MRD) outcomes and comparisons with the ZUMA-3 trial for obecabtagene autoleucel (obe-cel) in relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Dr. O’Dwyer to Dr. Logan: There’s been a lot of real-world outcomes data with brexu-cel. Can you share some ASH 2024 data updates from CIBMTR and whether these data reflect what you have observed in your day-to-day clinical practice?
- Resource links:
ASH 2024 poster 5092, Wudhikarn K et al, brexu-cel CIMBTR registry updates , or see Appendix 2. - Dr. O’Dwyer to Dr. Molina: One of the biggest updates in ALL is the recent FDA approval of obe-cel. Can you review the FELIX trial, including study design and ASH 2024 updates on MRD outcomes? How is this trial similar and different than ZUMA-3?
Advertisement
Related to this article
Andrew Spencer, MBBS, FRACP, FRCPA, DM, breaks down phase 1 data for in vivo CAR T-cell therapy in relapsed/refractory multiple myeloma.
The FDA gave a CRL to the NDA seeking the approval of Orviglance for use in the detection of liver metastases in patients with severe kidney impairment.
The European Commission has approved epcoritamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma.
In a Roswell Park study, changes focused on standardization of care and donor selection, contributing to a 1-year overall survival rate of 92.6%.
Savolitinib received conditional NMPA approval in China for MET-amplified gastric or GEJ adenocarcinoma after prior systemic therapy, based on a 32.3% ORR.
Ropeginterferon alfa-2b has been approved by Health Canada for the treatment of adult patients with polycythemia vera.
Divarasib demonstrated superior PFS and OS versus sotorasib or adagrasib in the phase III Krascendo 1 trial in previously treated KRAS G12C–mutant NSCLC.
Faculty members gathered at an OncLive Scientific Interchange and Workshop to discuss individualizing care in EGFR-mutated NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus Lenalidomide/Rituximab Win EU Approval for R/R Follicular Lymphoma
2
TP53 Status and Time Toxicity Shape Sequencing Decisions in EGFR-Mutated NSCLC
3
Divarasib Outperforms First-Generation KRAS G12C Inhibitors in Phase 3 NSCLC Trial
4
Savolitinib Gains NMPA Approval for MET-Amplified Gastric and GEJ Adenocarcinoma
5